GlassScriptPhysician profile
Robert W Bynum
NPI 1477525111
$20,803.91
in general payments reported to CMS, 2019-2025
40 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,798 · 2020: $1,413 · 2021: $1,556 · 2022: $2,563 · 2023: $2,609 · 2024: $9,787 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,038 · Food and Beverage: $4,846 · Education: $315 · Travel and Lodging: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,037.50 |
| Food and Beverage | $4,845.95 |
| Education | $314.78 |
| Travel and Lodging | $276.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $6,410.74 | 2019-2025 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,798.52 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,071.38 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $917.82 | 2019-2025 | Krystexxa, Tavneos, Repatha |
| Horizon Therapeutics Plc | $844.99 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $786.91 | 2020-2025 | Acthar |
| Novo Nordisk INC | $774.89 | 2019-2025 | Ozempic |
| Opko Pharmaceuticals, LLC | $651.28 | 2019-2024 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $648.97 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $592.97 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $527.54 | 2019-2025 | |
| Akebia Therapeutics INC | $527.16 | 2019-2025 | Vafseo, Auryxia |
| Janssen Pharmaceuticals, INC | $469.83 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $409.38 | 2019-2025 | Verquvo, Capvaxive |
| Fresenius USA Marketing, INC. | $405.09 | 2020-2025 | Velphoro, Velphoro, Korsuva |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bynum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.